Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase-binding moiety covalently bonded to estrogen receptor-α (ERα)-targeting moiety through a linker reported to be useful for the treatment of breast cancer and infections.

Nerviano Medical Sciences Srl has synthesized substituted pyrrole carboxamides acting as cell division cycle 7-related protein kinase (CDC7) inhibitors reported to be useful for the treatment of cancer.

Arbutus Biopharma Corp. has described programmed cell death 1 ligand 1 (PD-L1) antagonists reported to be useful for the treatment of cancer, hepatitis B and hepatitis D viral infection.

Genfleet Therapeutics Inc. has divulged amine-substituted pyridine fused-ring compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) inhibitors reported to be useful for the treatment of cancer.

CSPC Pharmaceutical Group Ltd. announced that the National Medical Products Administration of the People’s Republic of China has granted approval to conduct clinical trials of the company’s antibody-drug conjugate candidate, SYS-6002.

Lysine-specific demethylase 1A (LSD1) is a monoamine oxidase encoded by the KDM1A...

Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) is a target for cancer...